| Emerging Treatment Options for Type 2 Diabetes. | |
| | |
MedLine Citation:
|
PMID: 20831513 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Type 2 diabetes mellitus (T2DM) is rapidly increasing in prevalence and is a major public health problem. It is a progressive disease which commonly requires multiple pharmacotherapy. Current options for treatment may have undesirable side effects (particularly weight gain and hypoglycaemia) and contraindications, and little effect on disease progression. Incretin based therapy is one of several newer therapies to improve glycaemia and is available in two different forms: dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) agonists. Use of these agents results in a "glucose-dependant" increase in insulin secretion and glucagon suppression resulting in improved glycaemia with low incidence of hypoglycaemia. DPP-4 inhibitors are oral drugs which are weight neutral, while GLP-1 agonists are injected subcutaneously and help promote weight loss while improving glycaemia. GLP-1 agonists have also been shown to increase beta cell mass in rat models. Bariatric surgery is another option for the obese patient with T2DM, with blood glucose normalising in over half of the patients following surgery. Other therapies in development for the treatment of T2DM include sodium-glucose transporter 2 (SGLT-2) inhibitors, glucagon receptor antagonists, glucokinase activators and sirtuins. In this article, we will review the various existing and emerging treatment options for T2DM. |
| | |
Authors:
|
Milan K Piya; Abd A Tahrani; Anthony H Barnett |
Related Documents
:
|
14664713 - Novel dipeptidyl peptidase iv resistant analogues of glucagon-like peptide-1(7-36)amide... 14693423 - Glp-1 inhibition of pancreatic islet cell apoptosis. 12612963 - New strategies for the treatment of secondary hyperparathyroidism. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2010-8-4 |
Journal Detail:
|
Title: British journal of clinical pharmacology Volume: - ISSN: 1365-2125 ISO Abbreviation: - Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-9-13 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7503323 Medline TA: Br J Clin Pharmacol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
© 2010 Schwarz Biosciences GmbH, UCB‐Group. Journal compilation © 2010 Blackwell Publishing Ltd. |
Affiliation:
|
Department of Diabetes and Endocrinology, Heart of England NHS Foundation Trust, Birmingham, UK. Centre for Endocrinology, Diabetes and Metabolism, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Investigation of respiration induced intra- and inter-fractional tumour motion using a standard Cone...
Next Document: The patterns of in vitro antimicrobial susceptibility and resistance of bacterial keratitis isolates...